Tunicamycin (TM) is an N-linked glycosylation (NLG) inhibitor with strong antitumor activity, the exact underlying molecular mechanism of which remains to be elucidated.
Acquisition of migratory and invasive capability is the initial step in metastasis. Epithelial-mesenchymal transition (EMT) is proposed to be a crucial mechanism that regulates the initial steps of metastatic progression. 4 CD44, a major adhesion molecule of the extracellular matrix, has been implicated in a wide variety of physiological processes, including leukocyte homing and activation, wound healing, and cell migration. 5 A previous study showed that CD44 alternative splicing is differentially regulated during EMT, resulting in a switch in expression from the variable exon-containing CD44v isoform to the standard isoform, CD44s, which is devoid of all CD44 variable exons. 6 Furthermore, a previous study showed that up-regulation of CD44 isoforms is associated with poorly differentiated HCC and shortened survival. activity and can target several types of tumors by reducing angiogenesis, inhibiting colony formation, and enhancing TRAIL-induced apoptosis. 9 Recently, we found that TM can reverse drug resistance and improve the efficacy of combination treatments for HCC by targeting the DPAGT1/Akt/ABCG2 pathway. 10 However, the effects of TM on the proliferation and migration of HCC cells are unknown.
In the present study, we investigated the effect of TM on the proliferation and migration of HCC cells as well as the underlying molecular mechanisms of these processes. We found that TM inhibits the proliferation and migration of HCC cells through CD44s and the ERK1/2 pathway. containing 10% heat-inactivated FBS (HyClone) and incubated at 37°C in a humidified atmosphere with 5% CO 2 . Chemicals and other reagents were purchased from Sigma-Aldrich unless otherwise specified.
| MATERIALS AND METHODS

| Cell lines and cell culture
MHCC
| Cell cycle analysis
For cell cycle analysis, cells were plated in a 6-well culture plate and grown for 24 hours. Cells were then incubated with 1 mM thymidine (Sigma-Aldrich) or 100 ng/mL nocodazole for 24 hours to synchronize cells at the G1/S or G2/M boundary. Cells were then treated with fresh media containing 2.5 lg/mL TM for different lengths of time.
Next, cells were trypsinized, washed twice with cold PBS and fixed with cold 70% ethanol at À20°C overnight. Cells were then washed twice with PBS and incubated with 10 mg/mL RNase A, 400 mg/mL propidium iodide and 0.1% Triton X in PBS at room temperature (RT) for 30 minutes. Cells were subsequently analyzed by flow cytometry.
| Apoptotic assay
Annexin V and 7-AAD staining was used to visualize apoptotic cells according to the manufacturer's instructions. Briefly, cells were seeded in 6-well plates and treated with TM at 2.5 lg/mL for 24 hours. Cells were then collected, washed twice with PBS and resuspended in 400 mL of 1 9 binding buffer. Next, 5 mL Annexin V-PE and 7-AAD solution was added, and the samples were incubated for 15 minutes at RT and analyzed by flow cytometry.
| MTT assay
Cells (5000/well) were seeded on 96-well plates for 24 hours and then exposed to different concentrations of TM. After incubation for 48 hours, 20 mL of 5 mg/mL MTT was added to the medium, and cells were incubated at 37°C for another 4 hours. Then the culture medium was discarded and 100 mL DMSO was added to each well to dissolve the precipitate. Absorbance (A) was measured at 570 nm using an ELISA plate reader, with background subtraction measurements done at 630 nm. The inhibition rate was calculated as follows: 
| Statistical analysis
Statistical analyses were carried out using SPSS 16.0 software. All data are presented as the mean AE SD. Two-group comparisons were analyzed using the two-tailed Student's t test. Three or more group comparisons were analyzed using one-way ANOVA. P < .05 was considered statistically significant. 
| Tunicamycin induces HCC cell apoptosis by
Bcl-2 family proteins
Apoptosis is also widely believed to be the major antiproliferative mechanism of anticancer drugs in many tumor cell types. Therefore, we also investigated the effect of TM on HCC cell apoptosis.
Increased apoptosis was observed in MHCC-97L cells treated with TM, implying that an increased rate of apoptosis could be one of the mechanisms of TM inhibition of cell proliferation ( Figure 2A ). To understand the mechanism by which TM induces cell apoptosis, we assessed the expression of Bcl-2 family proteins using western blotting. Results showed that the proapoptotic Bcl-2 family proteins Bim and Bid were up-regulated, and that the concomitant anti-apoptosis proteins Bcl-xL and Mcl-1 were down-regulated in TM-treated MHCC-97L cells ( Figure 2B ). However, the expression of Bcl-2 and PDCD4 did not change after TM treatment.
| Tunicamycin inhibits HCC cell migration through CD44s and the ERK1/2 pathway
Cancer cell migration is one of the crucial events in HCC metastasis.
Therefore, we detected the effect of TM on cell migration. Our results showed that TM inhibited HCC cell migration ( Figure 3A ).
The adhesion molecule CD44 plays a role in cell migration, metastasis and EMT. 12 Therefore, we detected the effect of TM on Our results showed that patients in the high CD44 expression group had shorter overall survival time than patients in the low expression group (log-rank, P = .017, Figure 5A) in publicly available gene expression array datasets (TCGA) using prognostic database PROGgene V2. 13 In addition, we found that there was a significant positive correlation between the expression of CD44 and Snail in HCC tissue using data sets from TCGA and GEO ( Figure 5B ). Furthermore, we found that there was a significant negative correlation between the expression of CD44 and E-cadherin in HCC tissue using data sets from TCGA and GEO (Figure 5C ). Therefore, all of these results suggested that high levels of CD44s expression are related to a high metastatic potential and EMT.
To investigate whether the migratory potential of HCC cells was determined by CD44s, a CD44s expression vector was stably These results showed that the inhibitory effect of TM on the proliferation and migration of HCC cells was partly a result of inhibition of CD44s glycosylation. In addition, we also detected the expression of CD44s mRNA in TM-treated HCC cells. Our results showed that TM suppressed the expression of CD44s mRNA in HCC cells (Figure 7C) . Therefore, these results suggest that TM inhibits the proliferation and migration of HCC cells by decreasing CD44s expression and altering its glycosylation.
| Tunicamycin inhibits transforming growth factor beta-mediated cell migration
Because transforming growth factor beta (TGF-b) signaling is one of the major driving factors of EMT in HCC, 18 we speculated that inhibition of TM during EMT might be attributed to a block- 
| DISCUSSION
Hepatocellular carcinoma is the most common primary malignancy of the liver in adults and the third most common cause of cancer death worldwide. In most cases, death results from metastasis at secondary sites. Tumor metastasis is a complex and multistage process, and tumor cells are required to express a variety of properties including altered adhesiveness, increased motility and invasive capacity to complete the metastatic process. 19 EMT is proposed to be a crucial mechanism that regulates the initial steps of metastatic progression. 20 Therefore, interruption of this step may be a strategy for the prevention and treatment of HCC metastasis. 4 In the present study, we showed that TM inhibited HCC cell proliferation by inducing G2/ M cell cycle arrest and cell apoptosis. TM inhibited the migration of HCC cells by decreasing activation of the CD44s-ERK1/2 signaling pathway.
Tunicamycin exerts a direct effect on HCC cells partially through inhibition of CD44. CD44 is a transmembrane glycoprotein that includes an extracellular region that interacts with growth factors and HA as well as a cytoplasmic moiety that is capable of interacting with cytoskeletal components. 21, 22 In this study, we found that TGF-b-promoted migration was reversed following TM treatment. Previous studies have also shown that inhibition of CD44 by an anti-CD44 mAb blocks tumor growth, metastasis, and invasion. 23 Furthermore, our previous results also showed that CD44s expression was upregulated in HCC tissues. 24 In addition, a previous study has indicated a shift in CD44 expression from variant isoforms (CD44v) to the standard isoform (CD44s) during EMT. 6 Our results showed that CD44v expression was decreased in TM-treated cells. However, CD44s expression was also decreased in TM-treated cells ( Figure S3 ). Therefore, we did not observe the shift in CD44 expression from CD44v to CD44s in TM-treated cells. Considering the accumulating body of evidence inhibited CD44 binding to HA. 26 Interactions between CD44, HA, and epidermal growth factor receptor (EGFR) promote the progression of various tumors by cross-activation of several signaling pathways. In head and neck squamous cell carcinoma, HA mediates the formation of a complex including CD44 and EGFR. 27 After the HA/CD44 interaction that recruits and forms a CD44-EGFR complex, multiple downstream signaling pathways are activated, further promoting diverse tumor progression behaviors. We also found that HA could activate phosphorylation of EGFR. In addition, CD44 and EGFR were colocalized in MHCC-97L cells examined by confocal microscopy ( Figure S4 ).
EGFR is a glycosylated protein localized to the apical domain of plasma membranes. 28 Our results showed that EGFR is glycosylated in hepatocellular carcinoma cells ( Figure S4 ). In addition, we found that TM inhibited EGFR expression by regulating its glycosylation.
F I G U R E 5 CD44 is associated with poor prognosis in hepatocellular carcinoma (HCC) patients. A, Patients with high expression levels of CD44 had shorter overall survival than patients with low expression levels. B, Correlation between CD44 expression and level of Snail in HCC tissues was analyzed using data sets from TCGA (The Cancer Genome Atlas) and GEO (Gene Expression Omnibus). C, Correlation between CD44 and E-cadherin expression in HCC tissues was analyzed using data sets from TCGA and GEO Furthermore, a recent study also showed that tunicamycin effectively enhanced TRAIL-induced apoptosis possibly through the inhibition of the EGFR pathway in human colon cancer cells. 29 Bourguignon et al.
previously reported the notion that CD44 can participate in the activation of EGFR in response to HA in squamous cell carcinoma cells. 30 Therefore, we speculated that TM inhibited HCC cell proliferation and migration possibly through regulation of the CD44s-mediated EGFR signaling pathways. However, these results need to be confirmed in the future.
Here we determined that TM inhibited the proliferation and migration of HCC cells. Moreover, we found that TM inhibited the proliferation and migration of HCC cells through attenuated activation of ERK1/2. These results will provide supportive evidence to uncover the antitumor mechanisms of TM. The ERK1/2 signaling pathway is believed to play an important role in cancer proliferation, apoptosis and migration. 31 The activation of ERK1/2 pathways in the progression of EMT in several cell lines has been widely established. 32, 33 Levels of phosphorylated forms of ERK1/2 are significantly higher in HCC models and human HCC tissue specimens than in healthy liver samples. 34, 35 Moreover, MAPK/ERK activity has been shown to be positively correlated with tumor size and aggressive tumor activity, 36,37 suggesting F I G U R E 6 Tunicamycin (TM) inhibits hyaluronic acid (HA)-induced cell migration by suppressing ERK1/2 activity in MHCC-97L cells. A, Expression levels of p-ERK1/2 and ERK1/2 were detected by western blotting in MHCC-97L cells treated with 50 lg/mL HA for the indicated length of time. B, Expression levels of p-ERK1/2 and ERK1/2 were detected by western blotting in MHCC-97L cells treated with 2.5 lg/mL TM, 50 lg/mL HA or 10 lmol/L U0126 alone or in combination for 12 h. C, MHCC-97L cells were treated with 2.5 lg/mL TM, 50 lg/mL HA or 10 lmol/L U0126 alone or in combination for 12 h, and migration was measured using transwell assays. *P < .05 that ERK1/2 activation reflects aggressive tumor activity in clinical conditions. Furthermore, we found that CD44s can activate the phosphorylation of ERK1/2 in HCC cells. Therefore, we
showed that TM inhibited the CD44-ERK1/2 signaling pathway to regulate the proliferation and migration of HCC cells.
Therefore, TM could be used as a potential agent against HCC metastasis.
In conclusion, our study suggests that the glycosylation inhibitor TM attenuates the proliferative and migratory abilities of HCC through the CD44s and ERK1/2 dependent pathway. CD44s or its downstream effector ERK1/2 might be able to be used as novel therapeutic targets for HCC therapy.
